Stay updated with breaking news from Jen Moses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good day and welcome to the G1 Therapeutics fourth quarter financial results conference call. At this time, all participants are in a listen-only mode.
01.03.2023 - - Achieved $31.3 Million in Net Revenue from Sales of COSELA (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million - - Announced Top Line Results from Pivotal Phase 3 ...
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
GTHX earnings call for the period ending June 30, 2022.
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights - read this article along with other careers information, tips and advice on BioSpace